Cyrius: accurate CYP2D6 genotyping using whole-genome sequencing data
- PMID: 33462347
- PMCID: PMC7997805
- DOI: 10.1038/s41397-020-00205-5
Cyrius: accurate CYP2D6 genotyping using whole-genome sequencing data
Erratum in
-
Publisher Correction: Cyrius: accurate CYP2D6 genotyping using whole-genome sequencing data.Pharmacogenomics J. 2022 Dec;22(5-6):308. doi: 10.1038/s41397-022-00287-3. Pharmacogenomics J. 2022. PMID: 36171418 Free PMC article. No abstract available.
Abstract
Responsible for the metabolism of ~21% of clinically used drugs, CYP2D6 is a critical component of personalized medicine initiatives. Genotyping CYP2D6 is challenging due to sequence similarity with its pseudogene paralog CYP2D7 and a high number and variety of common structural variants (SVs). Here we describe a novel bioinformatics method, Cyrius, that accurately genotypes CYP2D6 using whole-genome sequencing (WGS) data. We show that Cyrius has superior performance (96.5% concordance with truth genotypes) compared to existing methods (84-86.8%). After implementing the improvements identified from the comparison against the truth data, Cyrius's accuracy has since been improved to 99.3%. Using Cyrius, we built a haplotype frequency database from 2504 ethnically diverse samples and estimate that SV-containing star alleles are more frequent than previously reported. Cyrius will be an important tool to incorporate pharmacogenomics in WGS-based precision medicine initiatives.
Conflict of interest statement
XC, FS, NG, AM, CR, RJT, DRB, and MAE are employees of Illumina Inc.
Figures
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
